# CABRAMET (NCT03967522)

> Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

No report yet. It can be ordered.

- Drugs tested: cabozantinib
- Indication: metastatic renal cell carcinoma with brain metastases

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03967522
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Centre Leon Berard
- Conditions: Metastatic Renal Cell Carcinoma
- Interventions: Cabozantinib
- Enrollment: 26
- Primary outcome: The non progression rate in brain metastases at 6 months

## Indexed commentary on CABRAMET so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cabramet-nct03967522